374 related articles for article (PubMed ID: 27168011)
1. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
[TBL] [Abstract][Full Text] [Related]
2. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
3. Discovery of melanotransferrin as a serological marker of colorectal cancer by secretome analysis and quantitative proteomics.
Shin J; Kim HJ; Kim G; Song M; Woo SJ; Lee ST; Kim H; Lee C
J Proteome Res; 2014 Nov; 13(11):4919-31. PubMed ID: 25216327
[TBL] [Abstract][Full Text] [Related]
4. Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study.
Oikonomopoulou K; Scorilas A; Michael IP; Grass L; Soosaipillai A; Rosen B; Murphy J; Diamandis EP
Tumour Biol; 2006; 27(2):104-14. PubMed ID: 16557045
[TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family.
Peltier J; Roperch JP; Audebert S; Borg JP; Camoin L
J Proteomics; 2016 Oct; 148():139-48. PubMed ID: 27492143
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
7. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
Tamir A; Jag U; Sarojini S; Schindewolf C; Tanaka T; Gharbaran R; Patel H; Sood A; Hu W; Patwa R; Blake P; Chirina P; Oh Jeong J; Lim H; Goy A; Pecora A; Suh KS
J Ovarian Res; 2014 Dec; 7():109. PubMed ID: 25477184
[TBL] [Abstract][Full Text] [Related]
9. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
[TBL] [Abstract][Full Text] [Related]
10. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
11. Biochemical pathways mediated by KLK6 protease in breast cancer.
Pampalakis G; Zingkou E; Sidiropoulos KG; Diamandis EP; Zoumpourlis V; Yousef GM; Sotiropoulou G
Mol Oncol; 2019 Nov; 13(11):2329-2343. PubMed ID: 30980596
[TBL] [Abstract][Full Text] [Related]
12. Follistatin is a novel biomarker for lung adenocarcinoma in humans.
Chen F; Ren P; Feng Y; Liu H; Sun Y; Liu Z; Ge J; Cui X
PLoS One; 2014; 9(10):e111398. PubMed ID: 25347573
[TBL] [Abstract][Full Text] [Related]
13. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.
Haritos C; Michaelidou K; Mavridis K; Missitzis I; Ardavanis A; Griniatsos J; Scorilas A
Clin Exp Med; 2018 May; 18(2):203-213. PubMed ID: 29435805
[TBL] [Abstract][Full Text] [Related]
15. High serum levels of follistatin in patients with ovarian cancer.
Ren P; Chen FF; Liu HY; Cui XL; Sun Y; Guan JL; Liu ZH; Liu JG; Wang YN
J Int Med Res; 2012; 40(3):877-86. PubMed ID: 22906260
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
17. Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes.
Shin J; Kim G; Lee JW; Lee JE; Kim YS; Yu JH; Lee ST; Ahn SH; Kim H; Lee C
Cancer Sci; 2016 Jun; 107(6):828-35. PubMed ID: 27002480
[TBL] [Abstract][Full Text] [Related]
18. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
Planque C; Kulasingam V; Smith CR; Reckamp K; Goodglick L; Diamandis EP
Mol Cell Proteomics; 2009 Dec; 8(12):2746-58. PubMed ID: 19776420
[TBL] [Abstract][Full Text] [Related]
19. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
20. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
